This company has been marked as potentially delisted and may not be actively trading. NASDAQ:CSBR Champions Oncology (CSBR) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Champions Oncology Stock (NASDAQ:CSBR) Get Champions Oncology alerts:Sign Up Key Stats Today's Range$9.00▼$9.7250-Day Range$9.11▼$10.9652-Week Range$3.60▼$11.99Volume32,633 shsAverage Volume15,101 shsMarket Capitalization$89.23 millionP/E Ratio32.38Dividend YieldN/APrice Target$12.00Consensus RatingModerate Buy Company Overview Champions Oncology, Inc. engages in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. Its technology platform, TumorGraft, is a novel approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. It uses its technology to offer solutions to Translational Oncology Solutions, which includes pharmaceutical and biotechnology companies; and Personalized Oncology, which assists physicians in developing personalized treatment options for their cancer patients. The company was founded by James M. Martell and David Sidransky on June 4, 1985 and is headquartered in Hackensack, NJ. Read More Champions Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreCSBR MarketRank™: Champions Oncology scored higher than 81% of companies evaluated by MarketBeat, and ranked 184th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingChampions Oncology has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Upside PotentialChampions Oncology has a consensus price target of $12.00, representing about 85.3% upside from its current price of $6.48.Amount of Analyst CoverageChampions Oncology has only been the subject of 1 research reports in the past 90 days.Read more about Champions Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Champions Oncology is 32.38, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 230.70.Price to Earnings Ratio vs. SectorThe P/E ratio of Champions Oncology is 32.38, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 84.52.Price to Book Value per Share RatioChampions Oncology has a P/B Ratio of 23.98. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.45% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently decreased by 4.02%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldChampions Oncology does not currently pay a dividend.Dividend GrowthChampions Oncology does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.08 Percentage of Shares Shorted1.45% of the float of Champions Oncology has been sold short.Short Interest Ratio / Days to CoverChampions Oncology has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Champions Oncology has recently decreased by 4.02%, indicating that investor sentiment is improving. News and Social Media0.0 / 5News Sentiment1.04 News Coverage This WeekMarketBeat has tracked 3 news articles for Champions Oncology this week, compared to 4 articles on an average week. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Champions Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders46.98% of the stock of Champions Oncology is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions41.30% of the stock of Champions Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Champions Oncology's insider trading history. Receive CSBR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Champions Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CSBR Stock News HeadlinesWomen's Champions League: Man Utd hold on to beat Atletico with 10 players - reactionOctober 16 at 2:52 PM | bbc.co.ukWomen's Champions League: Man Utd ahead but down to 10 players against AtleticoOctober 16 at 2:52 PM | bbc.co.ukBuy alert: Move $1,000 before Tesla’s Optimus launchElon's $1,000,000,000,000 payday Elon Musk just made his biggest insider purchase of Tesla stock ever. He's preparing for a "mind blowing" new launch that could see Tesla move away from electric cars... and into a new market. | Altimetry (Ad)Skechers World Champions Cup: U.S., Europe, International teams add sixth and final playerOctober 15 at 4:05 PM | msn.comPlayers Outraged After PGA Tour Champions Reduces Pension BenefitsOctober 10, 2025 | msn.comPGA Tour Champions pension pool cut by 20 percent, players unhappyOctober 10, 2025 | msn.comChampions Oncology, Inc. (NASDAQ:CSBR) Q1 2026 Earnings Call TranscriptSeptember 18, 2025 | insidermonkey.comChampions Oncology Earnings Call: Cautious Optimism Amid ChallengesSeptember 17, 2025 | msn.comSee More Headlines CSBR Stock Analysis - Frequently Asked Questions How were Champions Oncology's earnings last quarter? Champions Oncology, Inc. (NASDAQ:CSBR) announced its quarterly earnings data on Monday, September, 15th. The biotechnology company reported ($0.03) EPS for the quarter. The biotechnology company had revenue of $13.99 million for the quarter. Champions Oncology had a net margin of 5.19% and a trailing twelve-month return on equity of 87.76%. Read the conference call transcript. What other stocks do shareholders of Champions Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Champions Oncology investors own include Intel (INTC), Gilead Sciences (GILD), Micron Technology (MU), NVIDIA (NVDA), AT&T (T), Advanced Micro Devices (AMD) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings9/15/2025Today10/17/2025Fiscal Year End4/30/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryN/A Current SymbolNASDAQ:CSBR CIK771856 Webwww.championsoncology.com Phone(201) 808-8400Fax410-369-0390Employees143Year Founded2007Price Target and Rating Average Price Target for Champions Oncology$12.00 High Price Target$12.00 Low Price Target$12.00 Potential Upside/Downside+85.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($0.06) Trailing P/E Ratio32.50 Forward P/E RatioN/A P/E GrowthN/ANet Income$4.70 million Net Margins5.19% Pretax Margin4.99% Return on Equity87.76% Return on Assets9.95% Debt Debt-to-Equity RatioN/A Current Ratio0.93 Quick Ratio0.93 Sales & Book Value Annual Sales$56.94 million Price / Sales1.57 Cash Flow$0.45 per share Price / Cash Flow14.35 Book Value$0.27 per share Price / Book23.98Miscellaneous Outstanding Shares13,780,000Free Float7,305,000Market Cap$89.23 million OptionableOptionable Beta0.55 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:CSBR) was last updated on 10/18/2025 by MarketBeat.com Staff From Our PartnersTrump Issues Surprise Emergency OrderIs This Stock the 'Next Nvidia'? Billionaire Warren Buffett has been loading up on millions of shares of th...Altimetry | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAltucher: It Looks Like My Trump prediction is coming trueNew Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Tru...Paradigm Press | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredThis dark force is about to change everythingSomething unusual is unfolding inside the Republican Party — from Marjorie Taylor Greene breaking ranks to Ted...Porter & Company | SponsoredNext opportunity for crypto millionsThe floodgates have opened. Bitcoin and Ethereum ETFs are seeing record-breaking inflows, the biggest since...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Champions Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Champions Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
